Not to be administered via IV. Severe allergic reactions & bronchospasm. Local subcutaneous effects. Patient w/ renal, pulmonary or CV disease; prone to nausea & vomiting; preexisting cardiac disease & postural hypotension; advanced Parkinson's disease. Patient at risk for Torsades de pointes arrhythmia; serious underlying heart disease eg, congestive cardiac failure, or significant electrolyte disturbance. Hypokalemia eg, gastroenteritis or initiation of diuretic therapy; haemolytic anaemia & thrombocytopenia; possible cardiac symptoms eg, palpitations, syncope or near-syncope; somnolence & episodes of sudden sleep onset; exacerbated neuropsychiatric disturbances. Potential risk of dopamine dysregulation syndrome (DDS). Assess for CYP450 3A4 metabolism or QT interval. Perform ECG prior, during initiation phase, & as clinically indicated thereafter. Regularly monitor for the development of behavioural symptoms of impulse control disorders eg, pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating & compulsive eating. Reduce dose or taper-off discontinuation if behavioral symptoms of impulse control occur. Concomitant use w/ antihypertensives, levodopa, & dopamine. Combination w/ domperidone; drugs w/ narrow therapeutic range. Severe hepatic impairment. Not to be used during pregnancy. Lactation. Childn <18 yr. Elderly &/or debilitated patients.
Sign Out
